Congratulations to spin-out company Exonate who have reached their first patient milestone. Exonate aims to improve the treatment of patients with retinal vascular diseases, transforming the lives of those with sight loss with an eye drop to treat wet AMD and DME. As part of a randomised multicentre trial, the patients, who are in treatment at retinal centres in Australia, will be given either a placebo or a dose of EXN 407, the lead chemical compound in Exonate’s eye drops. The clinical trial is the culmination of an extensive period of research, which involved academics from the University of Bristol in its early stages, including Professor Dave Bates, formerly of Bristol’s School of Physiology and Pharmacology, now at the University of Nottingham. https://www.exonate.com/updates/